알레르기 비염엔 알레그라알레르기 비염엔 알레그라 Facebook ad: “하루는 24시간이죠? ”
Ran for 18 days, from January 13 to January 31, 2026, the last day Crush saw it.
Run by 알레르기 비염엔 알레그라 on Instagram. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 846753774820078
- Platforms
- Relaunches
- 0
Ad text
하루는 24시간이죠? ⏰ 하지만 알레르기 비염약은 1알로 충분해요! ⁶ 3세대 항히스타민제 알레그라⁷⁻¹⁰ 3가지 효과를 한 번에!⁴ ˉ ⁶ ✅최대 24시간 지속 효과⁶ ✅졸음 유발 감소⁵ ✅1시간 이내 효과 발현⁴ 알레르기비염엔 #알레그라¹ˉ³ #알레르기_비염엔_알레그라¹ˉ³ #알레르기비염 #allegra [광고심의필] 2025-1785-000500 MAT-KR-2600058-v1.0-01/2026 부작용이 있을 수 있으니 첨부된 '사용상의 주의사항'을 잘 읽고, 의사·약사와 상의하세요. [판매사] 오펠라헬스케어코리아㈜ [제조사] ㈜한독 [제품명] 알레그라 정 120mg [References] 1. Brożek JL et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J ALLERGY CLIN IMMUNOL. 2017.140(4), 950-958 2. Van Cauwenberge et al. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg. Clin Exp Allergy. 2000.30(6);891-899 3. T B Casale et al. Safety and Efficacy of Once-Daily Fexofenadine HCI in the treatment of autumn seasonal allergic rhinitis. Allergy and Astma Proc. 1999;20(3) 193-8. 4. Day J H et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride. Ann Allergy Asthma Immunol. 1997.79;533-540. 5. Smith SM et al. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opinion on Drug Metabolism & Toxicology. 2009;5(7);813-822. 6. Peter H et al. Double-blind, placebo-controlled study. Comparing the efficacy and safety of fexofenadine and cetirizine in seasonal AR. J ALLERGY CLIN IMMUNOL. 1999;104(5);927-33 7. Mark E et al. Efficacy and tolerability of 2nd and 3rd gen antihistamines. ANNALS OF ALLERGY, ASTHMA & IMMUNOL. 2010.104;518–522 8. Fein MN et al. CSACI position statement_Newer generation H1- antihistamines (3rd generation) are safer than first-generation H1- antihistamines. Allergy Asthma Clin Immunol. 2019.15(61);1-6 9. Anne K et al. Second-and third-generation antihistamines. DERMATOLOGIC THERAPY. 2000.13;327–336. 10. Thomas B et al. Next generation antihistamines : therapeutic rationale, accomplishments and advances. Expert Opinion
